Eli Lilly and Co
Pharmaceuticals
Eli Lilly and Co (LLY) Stock News
The latest LLY headlines and market coverage — 4 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
STLA FINAL DEADLINE: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages Stellantis N.V. Investors to Secure Counsel Before Important June 8 Deadline in Securities Class Action – STLA
Rosen Law Firm reminds Stellantis N.V. investors of the June 8, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that Stellantis made false statements about its earnings growth potential and electrification strategy, claiming the company was not well-positioned for battery-powered electric vehicle growth and would need to take significant charges to adjust its priorities.
- GlobeNewswire Inc.·
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Veritone, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VERI
Rosen Law Firm has filed a class action lawsuit on behalf of Veritone, Inc. investors who purchased securities between October 14, 2025 and April 14, 2026. The lawsuit alleges that Veritone made false statements and failed to disclose inaccurate revenue recording, misclassified costs, overstated financial metrics, and maintained deficient internal controls, leading to required financial statement restatements. Investors who wish to serve as lead plaintiff must file by July 20, 2026.
- GlobeNewswire Inc.·
IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX
Rosen Law Firm announces securities class action lawsuits against ImmunityBio, Inc. and other companies for allegedly making false and misleading statements. The firm is seeking lead plaintiffs with losses exceeding $100,000 before the May 26, 2026 deadline. According to the lawsuit, ImmunityBio's defendant Patrick Soon-Shiong materially overstated Anktiva's capabilities, resulting in false statements about the company's business and prospects.
- GlobeNewswire Inc.·Bearish
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ALDX
Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against Aldeyra Therapeutics, alleging the company made false and misleading statements about reproxalap clinical trial results. The lawsuit covers purchases between November 3, 2023 and March 16, 2026, with a lead plaintiff deadline of May 29, 2026.